CG Oncology (CGON) Projected to Post Earnings on Friday

CG Oncology (NASDAQ:CGON) is expected to be issuing its Q4 2025 results before the market opens on Friday, March 27th. Analysts expect the company to announce earnings of ($0.61) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, February 27, 2026 at 8:30 AM ET.

CG Oncology (NASDAQ:CGON) last posted its quarterly earnings data on Friday, February 27th. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.10. The firm had revenue of $2.32 million for the quarter. On average, analysts expect CG Oncology to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CG Oncology Stock Performance

Shares of CGON opened at $65.81 on Thursday. The stock has a fifty day moving average price of $57.54 and a two-hundred day moving average price of $46.78. CG Oncology has a 52-week low of $14.80 and a 52-week high of $69.35. The company has a market cap of $5.56 billion, a price-to-earnings ratio of -31.79 and a beta of 1.18.

Insider Buying and Selling at CG Oncology

In related news, Director James Mulay sold 1,964 shares of CG Oncology stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $63.50, for a total transaction of $124,714.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 7.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On CG Oncology

Hedge funds have recently bought and sold shares of the company. Picton Mahoney Asset Management acquired a new position in shares of CG Oncology in the 4th quarter valued at $118,000. Verition Fund Management LLC acquired a new stake in CG Oncology during the 3rd quarter worth $221,000. CIBC Bancorp USA Inc. acquired a new stake in CG Oncology during the 3rd quarter worth $240,000. Russell Investments Group Ltd. lifted its holdings in CG Oncology by 1,180.1% during the third quarter. Russell Investments Group Ltd. now owns 6,119 shares of the company’s stock worth $246,000 after acquiring an additional 5,641 shares in the last quarter. Finally, LPL Financial LLC grew its stake in CG Oncology by 9.8% in the fourth quarter. LPL Financial LLC now owns 6,201 shares of the company’s stock valued at $257,000 after acquiring an additional 551 shares during the period. 26.56% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently weighed in on CGON. Piper Sandler raised their price target on shares of CG Oncology from $55.00 to $70.00 and gave the company an “overweight” rating in a report on Friday, January 16th. Royal Bank Of Canada increased their price objective on CG Oncology from $61.00 to $73.00 and gave the company an “outperform” rating in a research report on Wednesday, January 21st. The Goldman Sachs Group reissued a “buy” rating and issued a $82.00 target price on shares of CG Oncology in a research note on Monday, January 12th. HC Wainwright boosted their target price on CG Oncology from $75.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CG Oncology in a research note on Wednesday, January 21st. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $69.00.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.